[1] Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients[J]. J Pharmacol Exp Ther, 1994, 271(1): 549-556.
[2] 韩现芹, 李 健, 王 群. 用药动学方法研究甘草和连翘对牙鲆CYP3A活性的影响[C]. 第十二届中国科协年会论文集. 福州,2010: 1-7.
[3] De wildt SN, Berns MJ, Van den anker JN. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study[J]. Ther Drug Monit, 2007, 29(2): 225-230.
[4] Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population[J]. Pharmacogenet Genomics, 2006, 16(9): 637-645.
[5] Shoun H, Fushinobu S. Physiological function, reaction mechanism, and structure of cytochrone P450nor[J]. Seikagaku, 2008, 80(6): 560-568.
[6] Burk O, Wojnowski L. Cytochrome P450 3A and their regulation[J]. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369(1): 105-124.
[7] Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie"[J]. Drug Metab Dispos, 2006, 34(5): 880-886.
[8] Akiyoshi T, Saito T, Murase S, et al. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants[J]. Drug Metab Dispos, 2011, 39(4): 724-728.
[9] Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism[J]. Pharmacogenetics, 2001, 11(9): 773-779.
[10] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4): 383-391.
[11] Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism[J]. Mol Pharmacol, 2002, 62(1): 162-172.
[12] Bodin K, Andersson U, Rystedt E, et al. Metabolism of 4 beta -hydroxycholesterol in humans[J]. J Biol Chem, 2002, 277(35): 31534-31540.
[13] Hukkanen J, Puurunen J, Hyotylainen T, et al. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity[J]. Br J Clin Pharmacol, 2015, 80(3): 473-479.
[14] Yang Z, Rodrigues AD. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?[J]. J Clin Pharmacol, 2010, 50(11): 1330-1338.
[15] Diczfalusy U, Nylen H, Elander P, et al. 4beta-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans[J]. Br J Clin Pharmacol, 2011, 71(2): 183-189.
[16] Goodenough AK, Onorato JM, Ouyang Z, et al. Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis[J]. Chem Res Toxicol, 2011, 24(9): 1575-1585.
[17] Dutreix C, Lorenzo S, Wang Y. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin[J]. Eur J Clin Pharmacol, 2014, 70(8): 915-920.
[18] Bjorkhem-bergman L, Backstrom T, Nylen H, et al. Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin[J]. Drug Metab Dispos, 2013, 41(8): 1488-1493.
[19] Leil TA, Kasichayanula S, Boulton DW, et al. Evaluation of 4beta-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model[J]. CPT Pharmacometrics Syst Pharmacol, 2014, 25(3):e120.
[20] Kasichayanula S, Boulton DW, Luo WL, et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects[J]. Br J Clin Pharmacol, 2014, 78(5): 1122-1134.
[21] Diczfalusy U, Kanebratt KP, Bredberg E, et al. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin[J]. Br J Clin Pharmacol, 2009, 67(1): 38-43.
[22] Furuta T, Suzuki A, Mori C, et al. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans[J]. Drug Metab Dispos, 2003, 31(11): 1283-1287.
[23] Shibata S, Takahashi H, Ono N, et al. Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis[J]. J Clin Pharm Ther, 2014, 39(2): 181-185.
[24] Hu ZY, Zhao YS, Wu D, et al. Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans[J]. Clin Chim Acta, 2009, 408(1-2): 92-97.[25] Peng CC, Templeton I, Thummel KE, et al. Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo[J]. Clin Pharmacol Ther, 2011, 89(6): 888-895.
[25] Marde Arrhen Y, Nylen H, Lovgren-sandblom A, et al. A comparison of 4beta-hydroxycholesterol : cholesterol and 6beta-hydroxycortisol : cortisol as markers of CYP3A4 induction[J]. Br J Clin Pharmacol, 2013, 75(6): 1536-1540.
[26] Ohno M, Yamaguchi I, Ito T, et al. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity[J]. Eur J Clin Pharmacol, 2000, 55(11-12): 861-865.
[27] Fleishaker JC, Pearson PG, Wienkers LC, et al. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability[J]. J Pharmacol Exp Ther, 1996, 277(2): 991-998.
[28] Shibasaki H, Hosoda K, Goto M, et al. Intraindividual and interindividual variabilities in endogenous cortisol 6beta-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans[J]. Drug Metab Dispos, 2013, 41(2): 475-479.
[29] Luo X, Zheng L, Cai N, et al. Evaluation of 6beta-hydroxycortisol and 6beta-hydroxycortisone as biomarkers for cytochrome P450 3A activity: insight into their predictive value for estimating oral immunosuppressant metabolism[J]. J Pharm Sci, 2015, 104(10): 3578-3586.
[30] Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians[J]. Pharmacogenet Genomics, 2008, 18(3): 201-208.
[31] Tremblay-franco M, Zerbinati C, Pacelli A, et al. Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human[J]. Steroids, 2015, 99(Pt B): 287-292.
[32] Mannheimer B, Wagner H, Ostenson CG, et al. No impact of vitamin D on the CYP3A biomarker 4beta-hydroxycholesterol in patients with abnormal glucose regulation[J]. PLoS One, 2015, 10(4): e0121984.
[33] Woolsey SJ, Beaton MD, Choi YH, et al. Relationships between endogenous plasma biomarkers of constitutive CYP3A activity with single time-point oral midazolam microdose phenotype in healthy subjects[J]. Basic Clin Pharmacol Toxicol, 2016,118(4):284-291.
[34] Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease[J]. Drug Metab Dispos, 2015, 43(10): 1484-1490.
[35] Suzuki Y, Itoh H, Sato F, et al. Significant increase in plasma 4beta-hydroxycholesterol concentration in patients after kidney transplantation[J]. J Lipid Res, 2013, 54(9): 2568-2572.
[36] Suzuki Y, Itoh H, Fujioka T, et al. Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients[J]. Drug Metab Dispos, 2014, 42(1): 105-110.
[37] Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention[J]. J Acquir Immune Defic Syndr (1999), 2012, 59(3): 266-273.
[38] Baranyai D, Muro E, Godtel-armbrust U, et al. Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity[J]. J Antimicrob Chemother, 2014, 69(7): 1933-1937.
[39] 卜书红, 张 健, 陆晓彤, 等. 儿童癫痫患者CYP酶活性与血清卡马西平浓度和临床疗效的相关性分析[J]. 医药导报, 2010, 29(4): 430-432.
[40] 张 健, 唐跃年, 刘海涛, 等. 急性淋巴细胞性白血病患儿化疗前后CYP3A酶活性研究[J]. 中国药师, 2007, 10(2): 110-112.
[41] Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients[J]. Br J Cancer, 2008, 99(8): 1239-1245.